Skip to main content
. 2017 Aug 17;16(4):5354–5362. doi: 10.3892/mmr.2017.7277

Figure 2.

Figure 2.

Effects of TGF-β1, SB203580, PD98059, SP600125 and OMT treatments on α-smooth muscle actin protein expression in myofibroblasts examined by immunocytochemistry (magnification, ×200). Cells were treated with TGF-β1 (20 ng/ml) for 24 h, with or without pretreatment with SB203580 (1×10−5 M), PD98059 (1×10−5 M), SP600125 (1×10−5 M), or different doses of OMT (L, 1.89×10−4 M; M, 3.78×10−4 M; or H, 7.56×10−4 M) for 1 h. TGF-β1, transforming growth factor-β1; OMT, oxymatrine; L, low-dose; M, medium-dose; H, high-dose.